![]() ![]() Which gives a possible trading interval of +/-$0.0585 (+/-6.26%) up or down from last closing price. Trading Expectations For The Upcoming Trading Day Of Friday 21stįor the upcoming trading day on Friday, 21st we expect Synthetics Biologics Inc to open at $0.92, and during the day (based on 14 day Average True Range), There is a buy signal from a pivot bottom found 1 days ago.) (This stock has low daily movements and this gives low risk. For the last week the stock has had daily average volatility of 0.778% However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0.0350 between high and low, or 3.89%. ![]() In general the stock tends to have very controlled movements and therefore the general risk is considered very low. Synthetics Biologics Inc finds support from accumulated volume at $0.92 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. The very low volume increases the risk and reduces the other technical signals issued. This causes a divergence and may be considered as an early warning, but it may not be. Volume fell during the last trading day while the price increased. A break-up above any of these levels will issue buy signals. On corrections up, there will be some resistance from the lines at $0.99 and $1.17. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. The Synthetics Biologics Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Some negative signals were issued as well, and these may have some influence on the near short-term development. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Further rise is indicated until a new top pivot has been found. A buy signal was issued from a pivot bottom point on Wednesday, October 19, 2022, and so far it has risen 1.32%. The new name, logo and branding elements were introduced to better reflect Theriva’s position as. TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. The new name, logo and branding elements were introduced to better reflect Theriva's position. TOVX), ("Theriva" or the "Company") is the new name of Synthetic Biologics, Inc. Synthetic Biologics Rebrands as Theriva Biologics | Morningstar The new name, logo and branding elements were introduced to better reflect. Or the “Company&CloseCurlyDoubleQuote ) is the new name of Synthetic Biologics, Inc. The new name, logo and branding elements were introduced to better reflect Theriva's position as a clinical-stage. ("Theriva" or the "Company") is the new name of Synthetic Biologics, Inc. The new name, logo and branding elements were introduced to better reflect Theriva. Synthetic Biologics Rebrands as Theriva Biologics physical and immunosuppressive barrier to cancer treatment SYN-004 (ribaxamase) which is designed to degrade certain commonly. On its last earning announcement, the company reported a loss of -0.59$ per share. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.Īt the moment the company doesn't generate any revenue. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |